Eisai Co. and JD Health have announced that Eisai’s Chinese subsidiary Eisai China Inc. and JD Health have established a joint venture company, Jingyi Weixiang（Shanghai）Health Industry Development Limited Company, to build a Health Service Platform for the elderly in China.

Japanese firm Eisai has over 35 years of experience in drug discovery activities in the area of Alzheimer’s disease/dementia with a rich development pipeline thereof. Eisai also has an understanding of the true needs of those living with dementia and their families as derived from the marketing of anti-Alzheimer's agent Aricept®, as well as a network of healthcare providers that includes medical specialists in dementia.

JD Health has a strong e-commerce business foundation, internet medical service know-how, and logistics infrastructure covering 99% of vast regions in China. Eisai and JD Health have now established a joint venture company in China that integrates the strengths of both companies, with JD Health investing 51% and Eisai China investing 49%.

The two companies aim to build a new One-Stop Health Service Platform for the elderly in China, where users can select and use the most suitable individual service from a variety of information and medical services.

The two companies will first build a platform with a special feature for dementia, and in the future plan to expand the platform to a wide range of diseases which frequently found in the elderly.

The One-Stop Health Service Platform will provide the following four core services online in China. The platform will launch these services beginning January 2021 in the order that they are authorized for provision and made ready.